Author:
Kraus M,Rückrich T,Reich M,Gogel J,Beck A,Kammer W,Berkers C R,Burg D,Overkleeft H,Ovaa H,Driessen C
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference22 articles.
1. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.
2. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC . Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630–639.
3. Glickman MH, Ciechanover A . The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373–428.
4. Wilkinson KD . Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000; 11: 141–148.
5. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G . The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801–805.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献